Holen Sie sich die Stockscreener-App
0.86
0.68%
0.0058
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8542
Offen:
$0.84
24-Stunden-Volumen:
233.85K
Relative Volume:
0.44
Marktkapitalisierung:
$19.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-38.85M
KGV:
-0.2972
EPS:
-2.8936
Netto-Cashflow:
$-44.99M
1W Leistung:
+26.40%
1M Leistung:
+2.98%
6M Leistung:
-35.34%
1J Leistung:
-15.27%
1-Tages-Spanne:
$0.84
$0.9011
1-Wochen-Bereich:
$0.72
$0.9375
52-Wochen-Spanne:
$0.63
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.875 | 19.11M | 0 | -38.85M | -44.99M | -2.8936 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
CTXR SEC FilingsCitius Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CTXR Technical Analysis & Stock Price Forecast - Intellectia AI
Breakouts Watch: What is Citius Pharmaceuticals Incs 5 year growth outlookTrade Risk Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology highlights early LYMPHIR commercial traction, expansion - TipRanks
Citius Oncology advances LYMPHIR launch and global expansion - TipRanks
Bond Watch: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Performance Recap & Technical Pattern Recognition Alerts - baoquankhu1.vn
Citius Oncology Provides Commercial Update on LYMPHIR Launch Highlighting Early Adoption and Expanding Clinical Development - Finviz
Citius Pharmaceuticals subsidiary reports strong early uptake and broad payer coverage for LYMPHIR launch - TradingView
Citius Oncology (CTXR) details early LYMPHIR launch uptake and $400M CTCL market - Stock Titan
Cancer centers move LYMPHIR onto formularies as coverage reaches 80% - Stock Titan
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development - Sahm
Citius Pharmaceuticals Inc (47N0.MU) balance sheet - Yahoo Finance UK
RSI Check: Is Citius Pharmaceuticals Inc stock good for income investors2026 Sector Review & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Citius Pharmaceuticals Inc (47N0.MU) recent insider transactions - Yahoo Finance UK
Rate Hike: Is Citius Pharmaceuticals Inc a cyclical or defensive stock2026 News Drivers & Low Risk Entry Point Guides - baoquankhu1.vn
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals to present CTCL clinical experience at USCLC Annual Workshop - tradersunion.com
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts - BioSpace
Citius Oncology to Participate in USCLC Annual Workshop 2026, Hi - GuruFocus
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR in Discussions with Leading Cutaneous Lymphoma Experts - Finviz
Aug Mood: Can Citius Pharmaceuticals Inc withstand a market correctionEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
Downgrade Watch: Is Citius Pharmaceuticals Inc benefiting from interest rate changesPortfolio Gains Summary & Fast Gain Stock Tips - baoquankhu1.vn
If You Invested $1,000 in Citius Pharmaceuticals Inc (CTXR) - Stock Titan
Macro Review: Should I buy Citius Pharmaceuticals Inc stock nowSell Signal & Growth Oriented Trading Recommendations - baoquankhu1.vn
Citius Oncology inks exclusive European distribution pact with Uniphar - MSN
Ideas Watch: Is Euroholdings Ltd stock trending bullishEarnings Recap Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Energy Moves: Does Citius Pharmaceuticals Inc align with a passive investing strategyMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
D Boral Capital maintains Citius Pharmaceuticals (CTXR) buy recommendation - MSN
Activity Recap: Is Citius Pharmaceuticals Inc a potential multi baggerIPO Watch & Stepwise Trade Execution Plans - baoquankhu1.vn
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Activity Recap: Is Citius Pharmaceuticals Inc stock good for income investors2026 Historical Comparison & AI Forecast Swing Trade Picks - baoquankhu1.vn
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - The Chronicle-Journal
CTXR: Citius Pharmaceuticals Receives Consistent 'Buy' Rating fr - GuruFocus
Citius Oncology reports positive phase 1 trial data for LYMPHIR By Investing.com - ca.investing.com
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - Finviz
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers - BioSpace
Citius Highlights Positive LYMPHIR Phase 1 Gynecologic Cancer Data - TipRanks
Citius Oncology reports positive phase 1 trial data for LYMPHIR - Investing.com
LYMPHIR combo shows activity in gynecologic cancers for Citius (CTXR) - Stock Titan
Market Review: Is Citius Pharmaceuticals Inc in a long term uptrend2026 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Bull Bear: Is Citius Pharmaceuticals Inc in a long term uptrendPortfolio Risk Summary & Verified Trade Idea Suggestions - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance
33 Stocks That Should Double in 3 Years - Insider Monkey
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma - BioSpace
Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data - TipRanks
Citius Oncology Announces Positive Phase 1 LYMPHIR Data - TipRanks
Phase 1 LYMPHIR data in high-risk DLBCL for Citius Oncology (Nasdaq: CTOR) - Stock Titan
Citius Pharmaceuticals subsidiary reports 86% ORR, 57% CR with LYMPHIR prior to CAR‑T in high‑risk DLBCL - TradingView
Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):